CAN AUTOMATIC FACIAL EXPRESSION ANALYSIS BE USED FOR TREATMENT OUTCOME ESTIMATION IN SCHIZOPHRENIA? by Bishay, M et al.
CAN AUTOMATIC FACIAL EXPRESSION ANALYSIS BE USED FOR TREATMENT
OUTCOME ESTIMATION IN SCHIZOPHRENIA?
Mina Bishay, Stefan Priebe and Ioannis Patras
Queen Mary University of London, UK
ABSTRACT
Negative symptoms of schizophrenia include expressive
deficits that are marked by a reduction in patients’ behaviour.
Analysing automatically non-verbal behaviour and exploiting
the results for estimating symptom severity has drawn atten-
tion recently. However, those approaches are not accurate
enough to be used for monitoring the changes in patient’s
symptom level during treatment interventions (i.e. the treat-
ment outcome). In this paper, we propose a method that di-
rectly addresses the problem of Treatment Outcome Estima-
tion (TOE) in schizophrenia – more specifically, is aimed at
determining whether specific symptoms have improved or not
by analysing jointly two videos of the same patient, one be-
fore and one after the treatment. The proposed architecture
builds on Recurrent Neural Networks (RNNs) that learn dif-
ferences in the patient behaviour before and after treatment.
We validate the method in videotaped interviews for symp-
tom assessment for 74 patients. Experimental results show
that the proposed architecture achieves promising results for
TOE in two different symptom assessment scales.
Index Terms— Facial expression analysis, schizophre-
nia, negative symptoms, treatment outcome estimation
1. INTRODUCTION
Schizophrenia is a severe mental health condition affecting
the way a patient thinks, feels, and behaves. Negative symp-
toms of schizophrenia are persistent [1], and have a greater
effect on patients’ quality of life in comparison to other symp-
toms [2]. These symptoms include impairments in the ex-
pression of emotion and speech (e.g. flat affect, impoverished
speech) [3], which are observed through a diminution in the
patients’ non-verbal behaviour during social/clinical interven-
tions [4]. For symptom assessment, non-verbal behaviour is
rated subjectively during clinical interviews.
Recently, automatic facial expression analysis has been
used for studying differences in behaviour between patients
with schizophrenia and healthy controls [5, 6], for diagnosis
and for the estimation of the severity of the symptoms [7, 8].
The work of Mina Bishay is a part of the Newton-Mosharafa PhD schol-
arship, which is jointly funded by the Egyptian Ministry of Higher Education
and the British Council.
However, the proposed methods for symptom estimation are
not suitable for determining whether the symptoms have im-
proved or not. The reason for that is that often the change
in negative symptoms is small [9], and falls within the error
margin of these methods.
In this paper, we propose a deep neural network archi-
tecture that directly addresses the problem of treatment out-
come estimation in schizophrenia. The architecture jointly
analyses 2 video interviews of a patient, one recorded before
and one recorded after the treatment, and gives as output the
treatment outcome, that is a binary label that encodes whether
the symptom has improved or not. The proposed architecture
consists of three main stages. Firstly, we detect automati-
cally the patient’s behaviour (facial expressions) in the pair of
videos. Then, we use a Recurrent Neural Network (RNN) for
learning the local differences/changes in the patient behaviour
over short concatenated clips from both videos. Finally, an-
other RNN uses the clip-level features for learning global (i.e.
patient-level) features, and outputs the treatment outcome.
The architecture is trained in a patient-independent man-
ner on a dataset of 74 patients with 148 video interviews - two
interviews for each patient, one before and one after complet-
ing a 10-week period of treatment. The videos were recorded
in uncontrolled conditions and in settings that are similar
to real clinical ones. We estimate the treatment outcome
of negative symptoms from two symptom assessment inter-
views; Clinical Assessment Interview for Negative Symptoms
(CAINS) [10], and Positive and Negative Syndrome Scale
(PANSS) [11]. Our architecture delivers promising results.
2. RELATEDWORK
In psychiatry, a lot of research focused on studying the non-
verbal behaviour of patients with schizophrenia [12, 13]. In
these works, the non-verbal behaviour was manually anno-
tated by human raters. Manual annotation is a rigorous, time-
consuming process. Moreover, non-verbal behaviour is rated
subjectively during clinical assessments. For these reasons,
several works investigate on the utilisation of Automatic Fa-
cial Expression Analysis (AFEA) for a) studying patient be-
haviour, and b) diagnosing schizophrenia.
Studying patient behaviour. Many works [5, 6, 14, 15]
focused on comparing patients’ behaviour to that of healthy
controls, by extracting and comparing behaviour-related fea-
tures of patients and controls. Furthermore, associations be-
tween these features and different symptoms were examined.
Different AFEA methods and features were used. In [5], the
probabilities of four emotion categories were detected in sin-
gle frames and then their average over the whole video was
calculated. In [6], Wang et al. used temporal facial infor-
mation for detecting 4 emotional and the neutral expressions,
then features like their occurrence frequencies were calcu-
lated. In [14, 15], 15 Action Units (AUs) were detected per
frame - in [14], features like the frequency of some single
and combined AUs were extracted, while in [15] Information
Theory measures were used for assessing the ambiguity and
distinctiveness of participants’ facial expressions. In all of
those studies, patients and controls were recorded in a bright
room while listening to emotional situations about their life.
Diagnosis of schizophrenia. In [7, 8, 16], AFEA was
used for the diagnosis or/and symptom severity estimation
in schizophrenia. In [7, 8], a commercial 3D facial analysis
tool was applied for extracting 23 AUs. Then, in [7] features
related to each AU intensity and dynamics were extracted,
while in [8], Tron et al. used clustering analysis over all AUs
for extracting 3 features related to expression flatness. These
features were then used for training a two-step SVM-based
algorithm, first for separation between patients and healthy
controls, and then for the estimation of some PANSS symp-
toms. In [7, 8], the subjects were recorded while answer-
ing emotionally evocative questions. In [16], Bishay et al.
proposed to turn the analysis from controlled contexts and
environments to settings that are similar to the ones found
in clinics. Furthermore, a deep architecture (called SchiNet)
was proposed for analysing patients’ facial expressions in the
wild, as well as estimating symptom severity by extracting
deep statistical features using Gaussian mixture model and
Fisher Vector layers.
To the best of our knowledge, no work addresses directly
the problem of treatment outcome estimation. Some of the
works reviewed above could be used for this purpose, by es-
timating the symptom level before and after treatment, and
then comparing the estimated levels. However, they do not
perform well because the change in these symptoms is typi-
cally small and falls within their margin of error.
3. THE DATA OF SCHIZOPHRENIA
In this work we use recordings and symptom annotations
from the “NESS” trial [17], that was collected for evaluating
body psychotherapy as a treatment for negative symptoms
of schizophrenia. The participants in the NESS trial were
recruited from mental health centres at 4 different locations
across the UK; East London, South London, Manchester, and
Liverpool. In total 275 participants were included in this trial.
All participants were diagnosed with schizophrenia, and had
a total negative symptoms score ≥ 18 on the PANSS scale.
The participants were assessed 3 times during the NESS
trial; before starting the treatment (baseline), after complet-
ing a 10-week treatment (end of treatment), and 6 months
after the end of the treatment (6 months follow-up). Assess-
ment interviews took between 40-120 minutes for each pa-
tient. Several scales were used for measuring the outcome of
the treatment such as PANSS [11] including negative, positive
and general psychopathology symptoms, and CAINS [10] in-
cluding experience-related and expression symptoms. Re-
searchers/psychologists conducted the assessment interviews
in a structured way that is similar to real life clinical settings.
The participants were video-recorded during the PANSS
and CAINS assessment. The NESS trial contains recordings
for 110 patients at baseline, 93 patients at end of treatment,
and 69 patients at 6 months follow-up – as not all of the pa-
tients accepted to be recorded at all sessions. In order to build
a dataset for the problem of treatment outcome estimation, we
select the patients who have been recorded at 2 out of the 3
sessions – this leads to a dataset of 88 patients, where each pa-
tient has two videos (commonly one at baseline and the other
at the end of treatment). Most of the videos were recorded at
a frame rate of 25 fps and a resolution of 1920×1080. The
average length of all the videos in our dataset is 42 minutes.
More information about the NESS trial can be found in [17].
4. PROPOSED METHOD
In this section we present the proposed method for treat-
ment outcome estimation. Figure 1 shows an overview of the
method. The architecture takes as input 2 video interviews of
a patient, one recorded before the treatment (video-1) and the
other recorded after (video-2), and outputs the treatment out-
come, that is, either improved (i.e. symptom level went down)
or not improved (i.e. symptom level stayed the same or went
up). That is, it directly addresses the problem of treatment
outcome estimation, posing it as a binary classification prob-
lem. The architecture consists of 4 stages; preprocessing,
automatic facial expression analysis, feature selection, and
sequence learning using Recurrent Neural Networks (RNNs).
4.1. Preprocessing Steps
We first slice the videos into fixed length clips of 15 seconds
each. The number of clips is kept fixed in the videos of the
same patient. To deal with a pair of videos with different
lengths, we divide the short video into N clips without over-
lap, and the long video into N equally-spaced clips, as shown
in Figure 1. The sliced clips are then down-sampled by a fac-
tor of 3 to reduce redundancy. A pair of clips (one from each
video) is then passed to the next processing steps.
For each frame in the paired clips, we detect the patient’s
body using [18], and then within the body region we extract
the face bounding-box and the smiling behaviour using the
SmileNet proposed in [19]. The extracted face is then scaled
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Fig. 1. The proposed architecture for treatment outcome estimation in schizophrenia.
to a fixed resolution of 100×100 and passed to the facial ex-
pression analysis architecture.
In some videos, the camera is positioned in such a way
that makes the patient’s face hard to be detected. In those
cases, even if the face is detected in some frames, it is hard to
be further analysed in terms of facial expressions. Therefore,
we consider only the videos in which we can successfully de-
tect faces in more than 90% of the frames – this leads to 74
patients out of the 88 included from the NESS trial. Note that
video-1 and video-2 of each patient should meet this condi-
tion in order for the patient to be included.
4.2. Automatic Facial Expression Analysis
Automatic Facial Expression Analysis (AFEA) is an active
area of research that only recently has been moving from
posed expressions and controlled environments, into sponta-
neous expressions in the wild (i.e. in real world conditions)
[20]. In this work we use the AFEA methods proposed in [16]
and in [19] – while the specific choice of the AFEA method
is not crucial, it is important that it can deal with illumina-
tion, pose and scale variations as those are common in the
data that we have. For each frame in the clips, we get an 11-
dimensional feature vector, 10 dimensions corresponding to
the probabilities of the presence of 10 facial action units (i.e.
facial expressions) [16], and one corresponding to the proba-
bility of the presence of a smile [19].
Finally, in order to reduce the effect of camera view-
points, illuminations levels, or/and occlusions by wearable
items (e.g. sunglasses), for each video, the mean over each
expression is calculated and subtracted from the expression
probabilities in the whole video (normalisation step).
4.3. Feature Selection
Feature selection is a crucial processing step in our architec-
ture, as a relatively small number of patients are available for
training. Sequential forward feature selection is used for se-
lecting the most relevant expressions to the estimated symp-
toms. The selected expressions from video-1 (before treat-
ment) and video-2 (after treatment) are concatenated at each
time step and used as input to the RNNs. Note that the same
expressions are selected in both videos.
4.4. Stacked RNNs for Treatment Outcome Estimation
Our architecture consists of two stacked RNNs (GRU-1,
GRU-2), shown in Figure 1, and takes as input pairs of clips
of facial expressions and outputs a soft decision, correspond-
ing to whether the facial expressions in the second sequence
(video-2) indicate an improvement in the symptoms in com-
parison to the first (video-1). That is, it treats the Treatment
Outcome Estimation (TOE) as a binary classification problem
using RNNs. In this work, we adopt a GRU [21] to learn the
temporal dynamics of the patients’ facial expressions, as it
has fewer parameters and generalises better on small datasets,
in comparison to LSTM [22].
The first network (GRU-1) is used as a local (clip-level)
feature extractor in our architecture. More specifically, GRU-
1 is trained using the selected expressions probabilities in the
pairs of clips for clip-level TOE. During training, GRU-1 is
supervised by the patient-level labels. GRU-1 consists of a
GRU layer with 16 hidden units, and a fully-connected layer
with a single sigmoid unit for classification.
The second network (GRU-2) is used as a global fea-
ture extractor. In particular, GRU-2 uses clip-level fea-
Table 1. Performance of our architecture as well as other SSE methods on TOE for the CAINS expression symptoms.
Symptom Facial Expression Vocal Expression Expressive Gestures Quantity of Speech
F1 Acc Avg F1 Acc Avg F1 Acc Avg F1 Acc Avg
Tron et al. [7] 0.18 0.62 0.40 0.27 0.59 0.43 0.29 0.61 0.45 0.21 0.60 0.41
Tron et al. [8] 0.14 0.67 0.41 0.31 0.66 0.49 0.22 0.67 0.45 0.07 0.62 0.35
SchiNet [16] 0.20 0.62 0.41 0.24 0.63 0.44 0.35 0.65 0.5 0.27 0.64 0.46
Ours 0.42 0.66 0.54 0.43 0.64 0.54 0.37 0.70 0.54 0.33 0.68 0.51
Table 2. Performance of our architecture as well as other SSE
methods on TOE for the PANSS negative symptoms.
Symptom Flat Poor Lack of
Affect Rapport Spontaneity
F1 Acc Avg F1 Acc Avg F1 Acc Avg
Tron et al. [7] 0.35 0.62 0.49 0.25 0.64 0.45 0.33 0.64 0.49
Tron et al. [8] 0.28 0.62 0.45 0.12 0.71 0.42 0.22 0.62 0.42
SchiNet [16] 0.31 0.64 0.48 0.20 0.67 0.44 0.21 0.60 0.41
Ours 0.40 0.66 0.53 0.30 0.68 0.49 0.46 0.71 0.59
tures/estimations for learning global (i.e. patient-level) fea-
tures, and outputs a soft binary label corresponding to the
treatment outcome. GRU-2 consists of a GRU layer with 2
hidden units, and a sigmoid classification layer.
5. EXPERIMENTS AND RESULTS
Training Settings. We use 74 pairs of videos (one for each of
the 74 patients) for training and testing our architecture using
a Leave-One-Subject-Out (LOSO) protocol. More specifi-
cally, for each fold in the LOSO, 67 patients are used for train-
ing, 6 patients for validation, and 1 patient for testing. Train-
ing is done in two steps, first pairs of sliced clips partitioned
from all patients’ videos are used for training GRU-1. The
output of GRU-1, that is the clip-level estimations, are then
used to train GRU-2. We use the binary cross-entropy clas-
sification cost for both networks. We train the RNNs using
stochastic gradient descent with adaptive learning rate (RM-
Sprop [23]), with a decay coefficient set to 0.7, and gradient
clipping to 100. The initial learning rate is set to 0.005 for
GRU-1, and 0.01 for GRU-2. The batch size is set to 256 se-
quences for GRU-1 and the training set size (i.e. 67 batches)
for GRU-2. We augment the dataset with extra samples by
considering each pair of videos in the training, validation and
testing sets as two data samples. Specifically, we change the
order of each pair of video-1 and video-2, and change the
ground truth label accordingly to get an extra data sample.
We train the proposed architecture for estimating the
change in negative symptoms, especially symptoms annotated
based on patients’ non-verbal behaviour during symptom as-
sessment interviews. In particular, 4 expression symptoms
(i.e. the Expression scale) in the CAINS interview [10], and
3 symptoms (flat affect, poor rapport, lack of spontaneity
and flow of conversation) in the PANSS interview [11], are
estimated. Note that a separate network is trained for each
symptom.
Symptom Severity Estimation (SSE). In order to test
how SSE methods perform on Treatment Outcome Estimation
(TOE), these methods are applied for estimating the symptom
severity before and after treatment independently, and then
the results are compared so as to reach a conclusion on the
treatment outcome. We compare our architecture with three
methods that have been proposed for SSE in schizophrenia
[7, 8, 16] – for a fair comparison, we have re-implemented
and re-trained those methods using the 74 patients. We used
the probabilities of the 11 detected expressions in the training
and the LOSO protocol for training/testing. For each fold,
we used 73 patients (146 videos) for training, and 1 patient
(2 videos) for testing. For [8, 16], we tried different number
of clusters or Gaussian components, and report the results of
the best performing ones (12 clusters for [8] and 32 Gaussian
components for [16]).
Results. In order to evaluate the performance of the pro-
posed architecture, we report both the accuracy and F1 score,
as well as the average over them. Table 1 and 2 summarise the
performance of the SSE methods and the proposed architec-
ture on TOE for the CAINS and PANSS symptoms, respec-
tively. The SSE methods show relatively low performance
when applied for TOE. The reason for that is that often the
change in negative symptoms during treatment is small [9],
and falls within their error margin. On average, the proposed
architecture outperforms the SSE methods in all the CAINS
and PANSS symptoms.
6. CONCLUSION
In this paper we propose an architecture that addresses di-
rectly the problem of TOE in schizophrenia. The architecture
consists of RNNs that use facial expressions for learning lo-
cal and global features over videos recorded before and after
treatment. Symptom assessment interviews recorded in set-
tings similar to real clinical ones are used in our analysis. Dif-
ferent expression-related negative symptoms from the PANSS
and CAINS scales are estimated. The proposed architecture
shows better performance in TOE, in comparison to other
methods proposed for SSE. However, the SSE and TOE meth-
ods are complementary. More specifically, the SSE methods
can be used during patients’ first sessions for diagnosis, while
the TOE methods can be used during treatment/follow-up ses-
sions for monitoring the change in symptoms levels.
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